Lipid rafts and HIV pathogenesis: Virion-associated cholesterol is required for fusion and infection of susceptible cells

AIDS Research and Human Retroviruses

Volumn 19, Issue 8, 2003, Pages 675-687

  Liao, Zhaohao ^a   Graham, David R ^a   Hildreth, James E K ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CYCLODEXTRIN; CHOLESTEROL;

ARTICLE; CELL ADHESION; CELL MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE; HOST CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION SENSITIVITY; LIPID COMPOSITION; LIPID MEMBRANE; PRIORITY JOURNAL; VIRION; VIROGENESIS; VIRUS ADSORPTION; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS INACTIVATION; VIRUS MORPHOLOGY; VIRUS PARTICLE; VIRUS PATHOGENESIS; WESTERN BLOTTING;

BETA-CYCLODEXTRINS; BLOTTING, WESTERN; CELL LINE; CHOLESTEROL; CYCLODEXTRINS; HIV INFECTIONS; HIV-1; HUMANS; VIRION;

EID: 0041823452     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922203322280900     Document Type: Article

References (79)

1. Resh MD: The ubiquitous nature of budding. Trends Microbiol 2001;9:57.
2. Freed EO: Viral late domains. J Virol 2002;76:4679-4687.
3. Martin-Serrano J, Zang T, and Bieniasz PD: HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat Med 2001;7:1313-1319.
4. Garrus JE, von Schwedler UK, Pornillos OW, et al.: Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 2001;107:55-65.
5. Patnaik A, Chau V, and Wills JW: Ubiquitin is part of the retrovirus budding machinery. Proc Natl Acad Sci USA 2000;97:13069-13074.
6. Mobius W, Ohno-Iwashita Y, van Donselaar EG, et al.: Immunoelectron microscopic localization of cholesterol using biotinylated and non-cytolytic perfringolysin O. J Histochem Cytochem 2002;50:43-55.
7. Simons K and Ikonen E: Functional rafts in cell membranes. Nature 1997;387:569-572.
8. Schroeder RJ, Ahmed SN, Zhu Y, London E, and Brown DA: Cholesterol and sphingolipid enhance the Triton X-100 insolubility of glycosylphosphatidylinositol-anchored proteins by promoting the formation of detergent-insoluble ordered membrane domains. J Biol Chem 1998;273:1150-1157.
9. Schnitzer JE, McIntosh DP, Dvorak AM, Liu J, and Oh P: Separation of caveolae from associated microdomains of GPI-anchored proteins [see comments]. Science 1995;269:1435-1439.
10. Robbins SM, Quintrell NA, and Bishop JM: Myristoylation and differential palmitoylation of the HCK protein-tyrosine kinases govern their attachment to membranes and association with caveolae. Mol Cell Biol 1995;15:3507-3515.
11. Arni S, Keilbaugh SA, Ostermeyer AG, and Brown DA: Association of GAP-43 with detergent-resistant membranes requires two palmitoylated cysteine residues. J Biol Chem 1998;273:28478-28485.
12. Feron O, Belhassen L, Kobzik L, et al.: Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem 1996;271:22810-22814.
13. Solomon KR, Mallory MA, and Finberg RW: Determination of the non-ionic detergent insolubility and phosphoprotein associations of glycosylphosphatidylinositol-anchored proteins expressed on T cells. Biochem J 1998;334(pt 2):325-333.
14. Zhang W, Trible RP, and Samelson LE: LAT palmitoylation: Its essential role in membrane microdomain targeting and tyrosine phosphorylation during T cell activation. Immunity 1998;9:239-246.
15. Rodgers W and Rose JK: Exclusion of CD45 inhibits activity of p561ck associated with glycolipid-enriched membrane domains. J Cell Biol 1996;135:1515-1523.
16. Nusrat A, Parkos CA, Verkade P, et al.: Tight junctions are membrane microdomains. J Cell Sci 2000;113:1771-1781.
17. Dorahy DJ, Lincz LF, Meldrum CJ, and Burns GF: Biochemical isolation of a membrane microdomain from resting platelets highly enriched in the plasma membrane glycoprotein CD36. Biochem J 1996;319:67-72.
18. Brown DA and London E: Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 1998;14:111-136.
19. Viola A, Schroeder S, Sakakibara Y, and Lanzavecchia A: T lymphocyte costimulation mediated by reorganization of membrane microdomains [see comments]. Science 1999;283:680-682.
20. Kabouridis PS, Janzen J, Magee AL, and Ley SC: Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signaling pathways in T lymphocytes. Eur J Immunol 2000;30:954-963.
21. Nix M and Stoffel W: Perturbation of membrane microdomains reduces mitogenic signaling and increases susceptibility to apoptosis after T cell receptor stimulation. Cell Death Differ 2000;7:413-424.
22. Nguyen DH and Hildreth JEK: Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol 2000;74:3264-3272.
23. Zheng YH, Plemenitas A, Linnemann T, Fackler OT, and Peterlin BM: Nef increases infectivity of HIV via lipid rafts. Curr Biol 2001;11:875-879.
24. Ono A and Freed EO: Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci USA 2001;98:13925-13930.
25. Niyogi K and Hildreth JEK: Human T-cell leukemia virus type 1 buds from lipid rafts. 9th Conference on Retroviruses and Opportunistic Infections, 2002, Abstract: 129.
26. Scheiffele P, Rietveld A, Wilk T, and Simons K: Influenza viruses select ordered lipid domains during budding from the plasma membrane. J Biol Chem 1999;274:2038-2044.
27. Bavari S, Bosio CM, Wiegand E, et al.: Lipid raft microdomains: A gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Meal 2002;195:593-602.
28. Manie SN, Debreyne S, Vincent S, and Gerlier D: Measles virus structural components are enriched into lipid raft microdomains: A potential cellular location for virus assembly. J Virol 2000;74:305-311.
29. Sapin C, Colard O, Delmas O, et al.: Rafts promote assembly and atypical targeting of a nonenveloped virus, rotavirus, in Caco-2 cells. J Virol 2002;76:4591-4602.
30. Pickl WF, Pimentel-Muinos FX, and Seed B: Lipid rafts and pseudotyping. J Virol 2001;75:7175-7183.
31. Liao Z, Cimakasky LM, Hampton R, Nguyen DH, and Hildreth JEK: Lipid rafts and HIV pathogenesis: Host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retroviruses 2001;17:1009-1019.
32. Pang L, Graziano M, and Wang S: Membrane cholesterol modulates galanin-GalR2 interaction. Biochemistry 1999;38:12003-12011.
33. Gimpl G, Burger K, and Fahrenholz F: Cholesterol as modulator of receptor function. Biochemistry 1997;36:10959-10974.
34. Gimpl G and Fahrenholz F: Human oxytocin receptors in cholesterol-rich vs. cholesterol-poor microdomalns of the plasma membrane. Eur J Biochem 2000;267:2483-2497.
35. Liu NQ, Lossinsky AS, Popik W, et al.: Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway. J Virol 2002;76:6689-6700.
36. Nisole S, Krust B, and Hovanessian AG: Anchorage of HIV on permissive cells leads to coaggregation of viral particles with surface nucleolin at membrane raft microdomains. Exp Cell Res 2002;276:155-173.
37. Popik W, Alce TM, and Au WC: Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. J Virol 2002;76:4709-4722.
38. Del Real G, Jimenez-Baranda S, Lacalle RA, et al.: Blocking of HIV-1 infection by targeting CD4 to nonraft membrane domains. J Exp Med 2002;196:293-301.
39. Puri A, Hug P, Jernigan K, Rose P, and Blumenthal R: Role of glycosphingolipids in HIV-1 entry: Requirement of globotriosyl-ceramide (Gb3) in CD4/CXCR4-dependent fusion. Biosci Rep 1999;19:317-325.
40. Hug P, Lin HM, Korte T, et al.: Glycosphingolipids promote entry of a broad range of human immunodeficiency virus type 1 isolates into cell lines expressing CD4, CXCR4, and/or CCR5. J Virol 2000;74:6377-6385.
41. Christian AE, Haynes MP, Phillips MC, and Rothblat GH: Use of cyclodextrins for manipulating cellular cholesterol content. J Lipid Res 1997;38:2264-2272.
42. Roos J, Maughan MF, Liao Z, Hildreth JEK, and Clements JE: A highly sensitive single-cycle infection assay for SIV and HIV-1 ultilizing a novel SIV LTR-lucifierase construct. Virology 2000;273:307-315.
43. Kilsdonk EP, Yancey PG, Stoudt GW, et al.: Cellular cholesterol elflux mediated by cyclodextrins. J Biol Chem 1995;270:17250-17256.
44. Rothblat GH, de LL, Atger V, et al.: Cell cholesterol efflux: Integration of old and new observations provides new insights. J Lipid Res 1999;40:781-796.
45. Liao Z, Roos J, and Hildreth JEK: Increased infectivity of HIV-1 particles bound to cell-surface and solid-phase ICAM-1 and VCAM-1 through acquired adhesion molecules LFA-1 and VLA-4. AIDS Res Hum Retroviruses 2000;16:355-366.
46. Orentas RJ and Hildreth JEK: Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV. AIDS Res Hum Retroviruses 1993;9:1157-1165.
47. Hoekstra D and Klappe K: Fluorescence assays to monitor fusion of enveloped viruses. Methods Enzymol 1993;220:261-276.
48. Nguyen DH and Taub D: CXCR4 function requires membrane cholesterol: Implications for HIV infection. J Immunol 2002;168:4121-4126.
49. Viard M, Parolini I, Sargiacomo M, et al.: Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host ceils. J Virol 2002;76:11584-11595.
50. Guyader M, Kiyokawa E, Abrami L, Turelli P, and Trono D: Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization. J Virol 2002;76:10356-10364.
51. Raffy S and Teissie J: Control of lipid membrane stability by cholesterol content. Biophys J 1999;76:2072-2080.
52. Loftsson T and Brewster ME: Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 1996;85:1017-1025.
53. Duzgunes N: Membrane fusion. Subcell Biochem 1985;11:195-286.
54. Papahadjopoulos D, Poste G, Schaeffer BE, and Vail WJ: Membrane fusion and molecular segregation in phospholipid vesicles. Biochim Biophys Acta 1974;352:10-28.
55. Chernomordik L, Chanturiya A, Green J, and Zimmerberg J: The hemifusion intermediate and its conversion to complete fusion: Regulation by membrane composition. Biophys J 1995;69:922-929.
56. Kozlov MM and Markin VS: On the theory of membrane fusion. The adhesion-condensation mechanism. Gen Physiol Biophys 1984;3:379-402.
57. Lee J and Lentz BR: Evolution of lipidic structures during model membrane fusion and the relation of this process to cell membrane fusion. Biochemistry 1997;36:6251-6259.
58. Garcia RA, Pantazatos SP, Pantazatos DP, and MacDonald RC: Cholesterol stabilizes hemifused phospholipid bilayer vesicles. Biochim Biophys Acta 2001;1511:264-270.
59. Huttner WB and Zimmerberg J: Implications of lipid microdomains for membrane curvature, budding and fission. Curr Opin Cell Biol 2001;13:478-484.
60. Burger K, Gimpl G, and Fahrenholz F: Regulation of receptor function by cholesterol. Cell Mol Life Sci 2000;57:1577-1592.
61. Mall S, Broadbridge R, Sharma RP, East JM, and Lee AG: Self-association of model transmembrane alpha-helices is modulated by lipid structure. Biochemistry 2001;40:12379-12386.
62. Lu M, Blacklow SC, and Kim PS: A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995;2:1075-1082.
63. Chan DC, Fass D, Berger JM, and Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-273.
64. Yang C, Spies CP, and Compans RW: The human and simian immunodeficiency virus envelope glycoprotein transmembrane subunits are palmitoylated. Proc Natl Acad Sci USA 1995;92:9871-9875.
65. Rousso I, Mixon MB, Chen BK, and Kim PS: Palmitoylation of the HIV-1 envelope glycoprotein is critical for viral infectivity. Proc Natl Acad Sci USA 2000;97:13523-13525.
66. Saez-Cirion A, Nir S, Lorizate M, et al.: Sphingomyelin and cholesterol promote HIV-1 gp41 pretransmembrane sequence surface aggregation and membrane restructuring. J Biol Chem 2002;277:21776-21785.
67. Wang JK: The Nef protein of HIV-1 associates with rafts and primes T cells for activation. Proc Natl Acad Sci USA 2000;97:394-399.
68. Kotov A, Zhou J, Flicker P, and Aiken C: Association of Nef with the human immunodeficiency virus type 1 core. J Virol 1999;73:8824-8830.
69. Welker R, Kottler H, Kalbitzer HR, and Krausslich HG: Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase. Virology 1996;219:228-236.
70. Thompson DO: Cyclodextrins - enabling excipients: Their present and future use in pharmaceuticals. Crit Rev Ther Drug Carrier Syst 1997;14:1-104.
71. Szejtli J: Cyclodextrins: A new group of industrial basic materials. Nahrung 1985;29:911-924.
72. Irie T and Uekama K: Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 1997;86:147-162.
73. Khanna KV, Whaley KJ, Zeitlin L, et al.: Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J Clin Invest 2002;109:205-211.
74. Loftsson T and Olafsson JH: Cyclodextrins: New drug delivery systems in dermatology. Int J Dermatol 1998;37:241-246.
75. Francis SA, Kelly JM, McCormack J, et al.: Rapid reduction of MDCK cell cholesterol by methyl-beta-cyclodextrin alters steady state transepithelial electrical resistance. Eur J Cell Biol 1999;78:473-484.
76. Stankewich MC, Francis SA, Vu QU, Schneeberger EE, and Lynch RD: Alterations in cell cholesterol content modulate Ca(2+)-induced tight junction assembly by MDCK cells. Lipids 1996;31:817-828.
77. Choi YH and Toyoda Y: Cyclodextrin removes cholesterol from mouse sperm and induces capacitation in a protein-free medium. Biol Reprod 1998;59:1328-1333.
78. Cross NL: Effect of methyl-beta-cyclodextrin on the acrosomal responsiveness of human sperm. Mol Reprod Dev 1999;53:92-98.
79. Parinaud J, Vieitez G, Vieu C, Collet X, and Perret B: Enhancement of zona binding using 2-hydroxypropyl-beta-cyclodextrin. Hum Reprod 2000;15:1117-1120.